Subscriptions Central AfricaEast AfricaHorn of AfricaIndian OceanNorth AfricaSouthern AfricaWest AfricaAfrica / World Agriculture - NutritionCulture - ArtsEconomy - DevelopmentEnvironment - NatureGay - LesbianGender - WomenHealthHuman rightsLabourMediaPoliticsScience - EducationSocietyTechnologyTravel - Leisure From Behind By Country By Topic Chronological Press Releases Partner Media Contact Us
   
  

See also:
» 18.03.2010 - Ministers to adopt strategies to fight job scarcity
» 17.03.2010 - Trade experts discuss ways to help poor countries
» 04.03.2010 - Mercenary activities focus at Addis Ababa meeting
» 03.03.2010 - UNAIDS partner with rock icon to fight AIDS
» 25.02.2010 - Fight organised crime like a pandemic – Ban
» 25.02.2010 - Africa more vulnerable to non-communicable diseases’ deaths
» 19.02.2010 - World Gold Council welcomes IMF gold sales
» 15.02.2010 - Ethiopia and UK leaders to head climate change team

Africa
Economy - Development | Society | Human rights | Health

Seven African states in Malaria trial

afrol News, 9 November - Seven African countries will take part in a historic malaria vaccine trials, as the world scientists strive to root out Africa’s number one killer.

The GlaxoSmithKline Biologicals' (GSK Bio) RTS,S trial which is expected to involve up to 16,000 children in Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique and Tanzania is on schedule, with more than 5,000 children already enrolled, according to the researchers.

The medication is the first malaria vaccine candidate to demonstrate significant efficacy during early development to warrant Phase III testing.

According to the researchers, attending the 5th Multilateral Initiative on Malaria Pan-African Malaria Conference held in Nairobi recently, a malaria vaccine has eluded scientists for decades, yet it is widely believed that only a vaccine can help eradicate the disease.

If successful, the vaccine will complement existing interventions, such as treated bed nets and effective drug therapies.

Researchers said RTS,S is the first vaccine designed primarily for use in Africa, where malaria kills thousands of people every year, the majority of them children under the age of five.

Conducting the trial in seven different countries across Sub-Saharan Africa would help researchers to evaluate the vaccine candidate's efficacy in a variety of settings, with diverse patterns of malaria transmission.

The vaccine profile is intended primarily for infants, as they and children under the age of five are the most vulnerable to malaria.

Malaria, a preventable and treatable disease, is one of the biggest killers of young children in Africa. Overall, the disease, which is transmitted by mosquitoes, kills an estimated 1 million people annually, the vast majority of them in Africa.

One of the most effective preventive measures against malaria is to sleep under insecticide-treated bed nets, which are a finely woven barrier and kill most mosquitoes upon contact.


    E-mail this to a friend     Printable version

Related pages and feature
Current afrol News Top Stories
Africa
Economy - Development
Society
Human rights
Health
Affairs
Children
Children
Cooperation
Development
Diseases
Events
Medicine
Policy
Policy
Policy
Poverty
Social services
Social Services
» Egypt speculates over President's health
» Africa advised against coal power
» Uganda turning into an oil economy
» World longest toilet queue upcoming in Kenya
» Sierra Leone battles corruption
» Ethiopia commodity exchange sets example
» Nigeria Senate leader calls Gaddafi "mad man"
» Togo court confirms Faure re-election
» Swazi opposition asks for sanctions
» Election dates finally set for São Tomé


top of page about afrol News | news | countries | archive | services | feed back | español 

© afrol News. Reproducing or buying afrol News' articles.

   You can contact us at mail@afrol.com